| Name | Title | Contact Details |
|---|
Frontida BioPharm is a Minority-Owned Contract Development & Manufacturing Organization. We work collaboratively with our clients to bring new and improved products to the pharmaceutical market. By leveraging our team`s vast knowledge and experience we are able to improve the success of our client`s business and product development efforts. Frontida was launched by founding management team members of Frontage Laboratories. Having 15 years of success in the business Frontage remains a thriving CRO that has become a full service R&D organization located in PA, NJ, and China. With strong record of FDA compliance and quality service to global pharmaceutical and biotechnology companies, the Frontage team easily founded Frontida. While Frontage and Frontida remain affiliates, they are separate business entities.
Equiscript helps safety net providers better understand and grow their 340B pharmacy business. With a keen eye for detail, our skilled people assist our clients in the design and implementation of a home delivery pharmacy program intended to improve health outcomes by putting much-needed medicines into the hands of those patients in the communities we serve.
Capsa Healthcare, leading provider of medication carts, medical carts, computer carts, wall-mounted work stations & prescription tablet counters.
Triad Isotopes Inc is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics to treat severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH`s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company`s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell`s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer. ERYTECH is based in Lyon, France and Cambridge, MA, USA, and has manufacturing sites in Lyon, France, and Princeton, New Jersey, USA.